Recombinant Mouse Transmembrane protein 43 (Tmem43)

How does TMEM43 expression change during cardiac pathologies?

Studies using pressure overload-induced cardiac hypertrophy models have revealed that TMEM43 is downregulated in mouse hearts and cardiomyocytes following stimulation . This downregulation appears to be part of the pathological response in cardiac hypertrophy. Experimental evidence comes from aortic banding (AB) models in mice, where TMEM43 expression decreased significantly compared to sham controls . Similarly, in neonatal rat cardiomyocytes (NRCMs) stimulated with angiotensin II, TMEM43 expression was reduced . This pattern suggests that decreased TMEM43 levels may contribute to the pathogenesis of cardiac hypertrophy and subsequent heart failure, though the exact mechanisms remain under investigation.

What are the primary experimental models used to study TMEM43 function?

Researchers employ several experimental models to study TMEM43 function:

• Knockdown models: AAV9-shTMEM43 carrying the TnT promoter has been used to reduce TMEM43 expression in cardiomyocytes in vivo .

• Knock-in models: Tmem43-S358L knock-in mice have been created using homologous recombination methods to study the effects of the pathogenic S358L mutation . This model involves targeting exon 12 in the Tmem43 gene and replacing two nucleotides (c.1072 T → C and c.1073C→T) .

• Cell culture models: Neonatal rat cardiomyocytes (NRCMs) stimulated with angiotensin II and transfected with adenovirus to overexpress TMEM43 serve as an in vitro model .

• Genetic reference populations: Recombinant inbred BXD mice (cross between C57BL/6J and DBA/2J strains) provide a platform for systems genetics analysis of Tmem43-related pathways .

These models allow for comprehensive investigation of TMEM43 function in normal and pathological conditions across different experimental contexts.

How does the TMEM43-S358L mutation alter protein interactions and cellular pathways?

The TMEM43-S358L mutation significantly alters protein interactions and cellular pathways, particularly affecting ER-mitochondria communication and lipid metabolism. TurboID proteomics analysis comparing wild-type and S358L mutant TMEM43 revealed distinct differences in their interacting proteomes . Notably, VDAC2, a protein involved in metabolic regulation of lipids and part of the ER-mitochondrion contact site, showed reduced interaction with the S358L mutant form of TMEM43 .

This altered interaction may represent a plausible mechanism for miscommunication between the ER and mitochondria, subsequently perturbing lipid homeostasis . Supporting this hypothesis, proteomic analysis of fibroblasts from TMEM43-p.S358L carriers identified 11 significantly upregulated proteins (p<0.003), including those involved in fatty acid metabolism . Specifically, acyl-coenzyme A thioesterase 1 (ACOT1) and Malonate-CoA ligase (ACSF3), which regulate intracellular levels of free fatty acids and are expressed in human cardiomyocytes, showed strong upregulation .

Transmission electron microscopy (TEM) of fibroblasts from TMEM43-p.S358L carriers further revealed the accumulation of multilamellar bodies, providing structural evidence for dysregulation of lipid metabolism as a prominent pathomechanism in ARVC5 .

What are the transcriptomic signatures associated with TMEM43 dysfunction in cardiac tissue?

Systems genetics analysis using cardiac transcriptomes from BXD recombinant inbred mice has provided insights into the transcriptomic signatures associated with TMEM43 dysfunction. Genetic correlation analysis computed through Pearson's product-moment correlation revealed genes whose expression patterns correlate significantly with Tmem43 expression (P < 0.05) .

The analysis identified networks of genes involved in both cardiac and metabolic pathways that are perturbed by Tmem43 dysfunction . Validation of these findings in the Tmem43-S358L knock-in mouse model confirmed the dysregulation of these pathways at both the mRNA and protein levels . Quantitative RT-PCR analysis demonstrated significantly reduced levels of mutant Tmem43 expression in the heart, which was further validated by Western blot analysis .

These transcriptomic signatures highlight the multifaceted role of TMEM43 beyond structural functions, suggesting its involvement in regulating metabolic processes critical for cardiac function. The transcriptomic data provides potential targets for therapeutic intervention and biomarkers for early detection of TMEM43-associated pathologies.

How do experimental outcomes differ between TMEM43 knockdown and mutation models?

Significant differences exist between TMEM43 knockdown models and mutation models, providing complementary insights into TMEM43 function:

TMEM43 Knockdown Models (AAV9-shTMEM43):

• Result in reduced TMEM43 expression in both sham and AB groups compared to control (ScRNA-injected) mice .

• Lead to exacerbated cardiac hypertrophy following aortic banding, as evidenced by increased heart weight to body weight ratio (HW/BW), heart weight to tibia length ratio (HW/TL), lung weight to body weight ratio (LW/BW), and lung weight to tibia length ratio (LW/TL) .

• Associated with increased cardiomyocyte cross-sectional area (CSA) as measured by H&E staining .

TMEM43 Mutation Models (Tmem43-S358L knock-in):

• Born and develop normally but show cardiac dysfunction .

• Exhibit significantly reduced levels of mutant Tmem43 expression in the heart at both mRNA and protein levels .

• Demonstrate biventricular systolic dysfunction with significantly decreased left ventricular ejection fraction (LVEF) and right ventricular ejection fraction (RVEF) as measured by cardiac magnetic resonance imaging (cMRI) .

• Show evidence of altered protein interactions, particularly with VDAC2, affecting ER-mitochondria communication and lipid homeostasis .

• Display accumulation of multilamellar bodies in fibroblasts, indicating dysregulation of lipid metabolism .

These differences suggest that while reduced TMEM43 expression contributes to cardiac pathology, the S358L mutation introduces additional pathogenic mechanisms involving protein interactions and metabolic dysregulation that may more closely recapitulate the human disease phenotype.

What techniques are most effective for generating and validating TMEM43 knock-in mouse models?

Creating and validating TMEM43 knock-in mouse models requires a systematic approach combining genetic engineering, molecular verification, and functional assessment:

Generation of Knock-in Model:

• Targeting strategy: The most effective approach involves homologous recombination targeting the specific exon containing the mutation of interest. For the Tmem43-S358L model, exon 12 was targeted with a homologous recombination method to introduce the p.Ser358Leu substitution by replacing two nucleotides (c.1072 T → C and c.1073C→T) .

• Vector design: An MC1 retrieval vector with appropriate homology arms (AB and YZ) for recombination is crucial. For the Tmem43 model, these corresponded to 548 and 526 bp sequences within introns 11 and 12, targeting a 13537 bp region .

• Selection system: A removable neomycin resistance cassette (Neo) flanked with frt sites allows for selection of successfully targeted cells while enabling subsequent removal to minimize interference with gene expression .

Validation Approaches:

• Genotyping: LongAmp PCR mastermix from New England Biolabs has proven effective for genotyping targeted mice .

• Sequence verification: Direct sequencing of total cDNA confirms the correct mRNA sequence and the presence of the intended nucleotide substitutions .

• Expression analysis: Quantitative real-time PCR (qRT-PCR) and Western blotting verify appropriate Tmem43 mRNA and protein expression levels, respectively .

• Functional validation: Cardiac magnetic resonance imaging (cMRI) using a Bruker 7T scanner with prospective ECG gating provides comprehensive assessment of cardiac function, revealing phenotypic consequences of the mutation .

• Backcrossing: For genetic consistency, chimeric animals should be backcrossed at least seven times with the desired strain (e.g., C57BL/6J for compatibility with BXD genetic studies) .

This methodological framework ensures the generation of reliable knock-in models that accurately recapitulate the genetic mutation while minimizing confounding factors from the targeting approach.

What are the optimal protocols for cardiac function assessment in TMEM43 mutant mice?

Cardiac magnetic resonance imaging (cMRI) has emerged as the gold standard for assessing cardiac function in TMEM43 mutant mice, offering comprehensive evaluation of structural and functional parameters:

cMRI Protocol:

• Animal preparation: Anesthetize mice with oxygenated 1.5% isoflurane and maintain core temperature at 37°C using a heated platform .

• Equipment setup: Utilize a high-field scanner (Bruker 7T) with prospective ECG gating using pediatric ECG probes attached to the paws .

• Contrast enhancement: Administer gadopentetic acid (Gd-DTPA, 0.3–0.6 mmol/kg) intraperitoneally while the mouse is positioned in the scanner bore .

• Imaging sequences:

  • Delayed enhancement MRI using T1-weighted cine sequence

  • Short-axis cine imaging using segmented fast low angle shot (FLASH) sequence

  • Parameters: Slice thickness = 1.0 mm, matrix size = 256 × 256, in-plane resolution = 117 × 117 μm², echo time/repetition time (TE/TR) = 3/5.2 ms, flip angle = 20°, segments = 1

  • Acquire 15-20 cine frames during the cardiac cycle

  • Tagged images at middle, basal, and apical planes of the left ventricle

• Analysis parameters:

  • Left ventricular maximum circumferential strain (Ecc) using HARP software

  • Atrial and ventricular end diastolic volumes

  • Left and right ventricular ejection fractions (LVEF, RVEF) using Segment software

  • Diastolic function quantified as rate of change of Ecc in diastole

  • Maximum apical twist and rate of change in diastole

  • LV sphericity defined as ratio of LV maximum width to LV base-to-apex length at end diastole

This comprehensive approach enables detection of subtle functional changes in TMEM43 mutant mice, including the biventricular systolic dysfunction characteristic of the Tmem43-S358L model, providing valuable insights into disease progression and potential therapeutic interventions.

What are the recommended approaches for analyzing TMEM43 protein interactions in cardiac tissue?

Analysis of TMEM43 protein interactions in cardiac tissue requires sophisticated proteomic approaches to capture physiologically relevant interactions. Based on recent studies, the following methodologies are recommended:

Proximity-based Labeling Techniques:

• TurboID approach: This method has proven effective for studying TMEM43 interactions. Clone TurboID to both N- and C-terminal of TMEM43 (both wild-type and mutant forms) to comprehensively capture the interactome . This approach allows for identification of proteins in close proximity to TMEM43 under native conditions.

• Biotinylation assay: Following transfection of TurboID-TMEM43 constructs, perform biotinylation assays to label proteins in close proximity to TMEM43 .

Protein Isolation and Identification:

• Immunoprecipitation: Use streptavidin-beads to immunoprecipitate biotinylated proteins from cell lysates .

• On-beads digestion: Process immunoprecipitated proteins directly on beads to minimize sample loss and contamination .

• Mass spectrometry analysis: Analyze peptide fragments using high-resolution Orbitrap mass spectrometry for accurate protein identification and quantification .

Comparative Analysis Approaches:

• Differential interaction profiling: Compare the interacting proteomes of wild-type and mutant (e.g., S358L) TMEM43 to identify altered protein associations that may contribute to pathology .

• Pathway analysis: Apply systems biology approaches to map identified interacting proteins to cellular pathways and biological processes.

• Validation studies: Confirm key interactions using complementary techniques such as co-immunoprecipitation or proximity ligation assays.

By implementing these approaches, researchers have identified critical TMEM43 interactions, such as the reduced association between TMEM43-S358L and VDAC2, providing insights into the molecular mechanisms underlying ARVC5 pathogenesis through disrupted ER-mitochondria communication and perturbed lipid homeostasis .

How should researchers interpret contradictory findings between TMEM43 expression and cardiac function?

Contradictory findings regarding TMEM43 expression and cardiac function require careful interpretation considering multiple factors:

Context-dependent Effects:
The relationship between TMEM43 expression and cardiac function appears to be complex and context-dependent. While reduced TMEM43 expression has been observed in pressure overload-induced cardiac hypertrophy models , indicating a potential protective role, knockdown of TMEM43 using AAV9-shTMEM43 exacerbated cardiac hypertrophy following aortic banding . These seemingly contradictory findings suggest that:

• Timing considerations: The physiological downregulation of TMEM43 may represent an initial adaptive response, while sustained reduction through experimental knockdown may become maladaptive.

• Compensatory mechanisms: Acute vs. chronic TMEM43 reduction may trigger different compensatory pathways, explaining divergent outcomes.

• Cell-type specific effects: TMEM43 may function differently in cardiomyocytes compared to cardiac fibroblasts or endothelial cells.

Mutation vs. Expression Level Effects:
The Tmem43-S358L mutation results in both reduced protein levels and altered protein interactions . Researchers should consider whether phenotypic effects stem from:

• Reduced protein levels: Is it a loss-of-function effect due to reduced expression?

• Altered functionality: Does the mutation change protein interactions even at equivalent expression levels?

• Gain-of-toxic-function: Does the mutant protein acquire detrimental properties?

Analysis of the Tmem43-S358L model revealed reduced mutant Tmem43 expression and altered protein interactions, particularly with VDAC2 , suggesting that both mechanisms contribute to pathology.

Resolution Approaches:

• Rescue experiments: Reintroducing wild-type TMEM43 in knockdown models can distinguish between specific and non-specific effects.

• Dose-response studies: Varying the degree of TMEM43 knockdown or overexpression can reveal threshold effects.

• Temporal analysis: Examining cardiac function at multiple timepoints may reveal transition points between adaptive and maladaptive responses.

By systematically addressing these considerations, researchers can reconcile apparently contradictory findings and develop a more nuanced understanding of TMEM43's role in cardiac physiology and pathology.

What are the common technical challenges in TMEM43 research and how can they be addressed?

Researchers working with TMEM43 face several technical challenges that require specific troubleshooting approaches:

Challenge 1: Low protein detection sensitivity
TMEM43 can be difficult to detect by Western blotting due to its transmembrane nature and relatively low abundance.

Solutions:

• Use membrane protein extraction protocols optimized for transmembrane proteins

• Employ enhanced chemiluminescence (ECL) detection systems with increased sensitivity

• Consider using epitope-tagged recombinant TMEM43 in experimental systems

• Validate antibodies thoroughly using knockout controls to ensure specificity

Challenge 2: Variability in genetic models
Knock-in and knockout models may show variability in phenotype expression.

Solutions:

• Backcross mice at least seven times to achieve genetic homogeneity (as done with Tmem43-S358L mice crossed to B6 background)

• Use littermate controls exclusively

• Increase sample sizes to account for biological variability

• Consider using genetic reference populations (GRPs) like the BXD strains to boost effective heritability

Challenge 3: Complex data analysis in systems genetics approaches
Processing and interpreting microarray and proteomic data presents analytical challenges.

Solutions:

• Apply robust normalization methods like Robust Multichip Array (RMA)

• Use modified Z-score transformations to facilitate interpretation of expression differences

• Implement standardized correlation thresholds (e.g., Pearson's product correlations with P < 0.05 for significant correlations)

• Utilize literature correlation analysis (r > 0.1) to identify genes described by similar terminology in published papers

Challenge 4: Reproducing the human disease phenotype in mouse models
Mouse models may not fully recapitulate human ARVC5 features.

Solutions:

• Use comprehensive phenotyping approaches, particularly cMRI, to detect subtle cardiac changes

• Consider age-dependent phenotype development, examining mice at multiple time points

• Compare multiple models (knockdown, knock-in) to distinguish mutation-specific from expression-level effects

• Supplement mouse studies with human cell-based models (e.g., induced pluripotent stem cell-derived cardiomyocytes)

By implementing these technical solutions, researchers can overcome common challenges in TMEM43 research and generate more reliable and translatable data.

How can systems genetics approaches enhance understanding of TMEM43 function?

Systems genetics approaches offer powerful frameworks for understanding TMEM43 function by connecting genetic variation to molecular and phenotypic outcomes through multiple analytical layers:

Advantages of Systems Genetics for TMEM43 Research:

• Enhanced Statistical Power: Utilizing animal recombinant inbred (RI) genetic reference populations (GRP), particularly BXD strains, significantly boosts effective heritability because each isogenic RI line and its stable genome can be replicated in controlled environments . This approach overcomes limitations of traditional knockout or transgenic studies by capturing natural genetic variation effects.

• Multi-level Integration: Systems genetics enables integration of:

  • Genetic variation (genotype)

  • Gene expression (transcriptome)

  • Protein interactions (proteome)

  • Metabolic changes (metabolome)

  • Phenotypic outcomes (phenome)

  This multi-level analysis reveals how TMEM43 functions within broader biological networks rather than in isolation.

Implementation Methodology:

• Genetic Correlation Analysis: Computing Pearson's product-moment correlations between TMEM43 expression and all other genes across BXD strains identifies genetically co-regulated genes . This network of correlations reveals functional associations that may not be apparent in direct interaction studies.

• Pathway Enrichment Analysis: Identifying biological pathways enriched among TMEM43-correlated genes reveals its functional context. Studies with BXD mice have shown TMEM43-correlated genes affect cardiac and metabolic homeostasis pathways .

• Validation in Targeted Models: Findings from systems genetics analyses can be validated in targeted models like the Tmem43-S358L knock-in mouse, as demonstrated by the identification of differentially expressed genes between mutant and wild-type mice that confirm pathway predictions from BXD analysis .

• Data Transformation and Normalization: Robust normalization using methods like RMA followed by Z-score transformation (producing values with mean of 8 and standard deviation of 2) enables meaningful comparison of expression differences where a twofold difference corresponds to approximately 1-unit change .

By applying these systems genetics approaches, researchers have identified TMEM43-mediated genetic networks that predict perturbations in cardiac and metabolic homeostasis, providing a comprehensive understanding of how TMEM43 dysfunction contributes to disease pathogenesis through multiple interconnected pathways rather than through isolated mechanisms .

What emerging technologies could advance TMEM43 research?

Several cutting-edge technologies show promise for advancing TMEM43 research:

CRISPR-based Approaches:

• Base editing: Precise modification of the S358L mutation without DNA double-strand breaks could create more accurate disease models with fewer off-target effects.

• Prime editing: This newer CRISPR variant could enable installation of the S358L mutation with higher fidelity than traditional homologous recombination methods.

• CRISPR activation/inhibition: CRISPRa/CRISPRi systems could enable temporal and tissue-specific modulation of TMEM43 expression without permanent genetic changes.

Advanced Imaging Technologies:

• Super-resolution microscopy: Techniques like STORM and PALM could resolve TMEM43 localization at the nuclear envelope and ER with nanometer precision, clarifying its subcellular distribution in normal and pathological states.

• Live-cell imaging: Fluorescent protein tagging combined with live-cell microscopy could track TMEM43 dynamics and interactions in real-time.

• Correlative light and electron microscopy (CLEM): This approach could connect TMEM43 localization with ultrastructural features like the multilamellar bodies observed in S358L fibroblasts .

Multi-omics Integration:

• Spatial transcriptomics: Mapping gene expression patterns with spatial resolution could reveal region-specific changes in TMEM43-related genes within the heart.

• Single-cell proteomics: Analysis of protein expression at the single-cell level could uncover cell-type specific responses to TMEM43 dysfunction.

• Lipidomics: Comprehensive analysis of lipid species could further characterize the lipid metabolism dysregulation suggested by current research .

Translational Models:

• Human iPSC-derived cardiomyocytes: Patient-specific or engineered iPSC-derived cardiomyocytes carrying the S358L mutation could bridge the gap between mouse models and human disease.

• Organoids: Cardiac organoids incorporating multiple cell types could model complex tissue-level consequences of TMEM43 dysfunction.

• Tissue-on-chip: Microfluidic platforms could enable controlled studies of TMEM43's role in cardiomyocyte function under various mechanical and biochemical conditions.

These technologies could address current limitations in understanding TMEM43 biology and accelerate development of therapeutic strategies for TMEM43-associated diseases.

What are the unexplored aspects of TMEM43 biology that warrant investigation?

Despite significant advances, several critical aspects of TMEM43 biology remain unexplored:

Structural Biology:
The three-dimensional structure of TMEM43 remains unresolved, limiting understanding of how the S358L mutation alters protein function. Cryo-electron microscopy or X-ray crystallography studies could reveal:

• The structural consequences of the S358L mutation

• Protein domains critical for interactions with partners like VDAC2

• Potential ligand-binding sites that might be pharmacologically targeted

Developmental Roles:
While TMEM43's role in adult cardiac pathology is being elucidated, its function during cardiac development remains unclear:

• Does TMEM43 contribute to cardiomyocyte differentiation or maturation?

• Are there developmental compensatory mechanisms that explain why Tmem43-S358L mice are born normally despite later developing cardiac dysfunction?

• Could developmental TMEM43 function inform regenerative approaches for cardiac repair?

Cell Type-Specific Functions:
Current research has focused primarily on cardiomyocytes, but TMEM43 may have distinct roles in other cardiac cell types:

• Cardiac fibroblasts and their potential contribution to fibrosis in ARVC5

• Endothelial cells and possible vascular phenotypes

• Specialized conduction system cells and their relationship to arrhythmias in ARVC5

Metabolic Regulation:
Emerging evidence suggests TMEM43 involvement in lipid metabolism , but many questions remain:

• Does TMEM43 directly regulate lipid transport or metabolism?

• How does TMEM43 contribute to ER-mitochondria communication?

• Are there TMEM43-dependent metabolic pathways that could be targeted therapeutically?

Non-cardiac Functions:
TMEM43's expression is not limited to the heart, suggesting unexplored roles in other tissues:

• TMEM43's role in cancer progression, particularly in pancreatic cancer where its expression correlates with poor survival

• Potential functions in other organs with high energy demands like the liver or skeletal muscle

• Implications for systemic metabolic regulation

Investigation of these unexplored aspects would provide a more comprehensive understanding of TMEM43 biology and potentially reveal new therapeutic approaches for TMEM43-associated diseases beyond current cardio-centric strategies.

What therapeutic strategies might target TMEM43-associated pathways in cardiomyopathies?

The growing understanding of TMEM43 biology suggests several potential therapeutic approaches for TMEM43-associated cardiomyopathies:

Gene-based Therapies:

• Gene replacement: AAV-mediated delivery of wild-type TMEM43 could compensate for reduced expression in S358L carriers.

• Allele-specific silencing: Antisense oligonucleotides or siRNA targeting specifically the mutant allele could reduce expression of pathogenic TMEM43 while preserving wild-type function.

• CRISPR-based correction: In vivo base editing could potentially correct the S358L mutation in cardiomyocytes, though delivery challenges remain significant.

Protein Interaction Modulators:

• VDAC2 interaction stabilizers: Small molecules that stabilize the interaction between TMEM43 and VDAC2 could counteract the reduced interaction observed with the S358L mutation .

• ER-mitochondria tethering enhancers: Compounds that promote ER-mitochondria contacts could compensate for disrupted communication resulting from altered TMEM43 function.

Metabolic Interventions:

• Lipid metabolism regulators: Given the upregulation of fatty acid metabolism enzymes like ACOT1 and ACSF3 in TMEM43-S358L carriers , targeted modulation of these pathways might ameliorate disease progression.

• Multilamellar body reduction: Therapies that reduce the accumulation of multilamellar bodies observed in S358L fibroblasts could address downstream consequences of lipid dysregulation .

Anti-fibrotic Approaches:
As fibrosis is a hallmark of ARVC5, anti-fibrotic therapies could slow disease progression:

• TGF-β pathway inhibitors: These could potentially reduce fibrotic remodeling in the heart.

• Matrix metalloproteinase modulators: Targeting the extracellular matrix remodeling process might preserve cardiac function.

Biomarker-guided Interventions:
Identification of biomarkers associated with TMEM43 dysfunction could enable personalized therapeutic approaches:

• Early intervention: Treating presymptomatic mutation carriers based on biomarker profiles before phenotypic manifestation.

• Response monitoring: Using biomarkers to track therapeutic efficacy and adjust treatment strategies accordingly.

Development of these therapeutic strategies will require further understanding of TMEM43 biology and careful validation in preclinical models before translation to clinical applications. The multifaceted nature of TMEM43 pathology suggests that combination approaches targeting multiple aspects of disease pathogenesis may ultimately prove most effective.